MetaCap

EyePoint Inc. (EYPT)

NASDAQ: EYPTIndustrialsBiotechnology: Laboratory Analytical InstrumentsUSD

0.2342-0.03 (-11.36%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

EYPT stock chart

Technical analysis

Key statistics

All statistics
Market cap
$26.65M
EPS (TTM)
-$3.97
52-week range
0.2277 – 19.11
Day range
0.2277 – 0.265
Volume / Avg
4.93M / 8.37M
Beta
—

52-week range

$0.2277$19.11

EYPT stock today

Shares of EyePoint (EYPT) finished lower on Nov 20 at $0.2342, a drop of 11.36% or $0.03 per share, versus the S&P 500's 3.70% decline. At this level, EYPT sits near the bottom of its 52-week range of $0.2277 to $19.11: 98.8% below the high, set on Dec 8, 2025 and 2.9% above the low. EYPT is down 98.7% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 98.3%.

EyePoint has posted a net loss over the last twelve months (EPS of -$3.97), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About EyePoint

Company profile

EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.

Industry
Biotechnology: Laboratory Analytical Instruments
CEO
Dr. Jay S. Duker M.D.
Headquarters
Watertown, MA
Employees
214

Financial highlights

Full financials

In fiscal 2025, EyePoint generated $31.4 million in revenue, down 27.5% from fiscal 2024, its first annual decline since 2024. EyePoint reported a net loss of $232.0 million, compared with a loss of $130.9 million a year earlier. Operating margin was -776.0%.

EyePoint annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$31.37M$43.27M$46.02M$41.40M$36.94M
Growth-27.50%-5.97%+11.14%+12.09%+7.27%
Net income$-231.96M$-130.87M$-70.80M$-102.25M$-58.42M
EPS (diluted)$-3.17$-2.32$-1.82$-2.74$-2.03

Analyst forecast

Forecast

Consensus (13 analysts)

buy

Avg. price target

$25.91+10963.19%

  • Strong buy 1
  • Buy 6
  • Hold 6
  • Sell 0
  • Strong sell 0

Target range

Low $4.00High $68.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 12, 2026
EPS actual vs est.
$-1.07 vs $-0.88
Surprise
-21.59%

EYPT news

All EYPT news

EyePoint peers

Industrials sector
EYPT peer companies
CompanyPrice% ChgMarket capCompare
PRPOPrecipio Inc.17.35-6.17%$31.11Mvs EYPT
CIRCCircle8 Group Inc.0.1361-12.25%$15.99Mvs EYPT
RPIDRapid Micro Biosystems Inc. Class A0.735-0.04%$37.37Mvs EYPT
HBIOHarvard Bioscience Inc.8.66-0.23%$39.60Mvs EYPT
BNGOBionano Genomics Inc.0.8222-7.11%$11.50Mvs EYPT
ASTCAstrotech Corporation (DE)3.50-0.85%$7.45Mvs EYPT
SEERSeer Inc. Class A1.36-1.81%$75.91Mvs EYPT
QTRXQuanterix Corporation1.96-3.45%$93.06Mvs EYPT

Indexes, lists and sector

EyePoint stock FAQ

What is EyePoint's stock price today?

EYPT last traded at $0.2342 as of Nov 20, 4:00 PM EST, down 11.36% on the day. Prices are delayed at least 15 minutes.

Does EyePoint pay a dividend?

No. EyePoint does not currently pay a regular cash dividend.

Who is EyePoint's CEO?

Dr. Jay S. Duker M.D. is the chief executive officer of EyePoint Inc., which has about 214 employees.

Has EYPT ever split its stock?

Yes. The most recent EYPT stock split was a 1-for-10 split on Dec 9, 2020, one of 2 splits on record.

What is the EYPT 52-week high?

The 52-week high for EYPT is $19.11 and the 52-week low is $0.2277. The stock is currently 98.8% below its high.

Compare EYPT